1.055
price down icon0.47%   -0.015
 
loading
Immunic Inc stock is traded at $1.055, with a volume of 65,494. It is down -0.47% in the last 24 hours and down -31.29% over the past month. Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
See More
Previous Close:
$1.07
Open:
$1.08
24h Volume:
65,494
Relative Volume:
0.09
Market Cap:
$93.68M
Revenue:
-
Net Income/Loss:
$-93.61M
P/E Ratio:
-0.3076
EPS:
-3.43
Net Cash Flow:
$-71.16M
1W Performance:
-2.29%
1M Performance:
-31.29%
6M Performance:
-16.14%
1Y Performance:
+0.00%
1-Day Range:
Value
$1.0504
$1.08
1-Week Range:
Value
$1.02
$1.13
52-Week Range:
Value
$0.97
$2.11

Immunic Inc Stock (IMUX) Company Profile

Name
Name
Immunic Inc
Name
Phone
(332) 255-9818
Name
Address
1200 AVENUE OF THE AMERICAS, NEW YORK
Name
Employee
85
Name
Twitter
@ImmunicInc
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
IMUX's Discussions on Twitter

Compare IMUX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
IMUX 1.0504 93.68M 0 -93.61M -71.16M -3.43
VRTX 446.87 115.74B 10.63B -479.80M -1.35B 13.33
REGN 741.28 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 590.30 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.22 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.67 24.49B 3.30B -501.07M 1.03B 11.54

Immunic Inc Stock (IMUX) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-21-22 Downgrade SVB Leerink Outperform → Mkt Perform
Sep-19-22 Resumed H.C. Wainwright Buy
Apr-15-21 Initiated Aegis Capital Buy
Mar-24-21 Initiated JMP Securities Mkt Outperform
Oct-02-20 Initiated SVB Leerink Outperform
Aug-26-20 Initiated Piper Sandler Overweight
Aug-07-20 Resumed ROTH Capital Buy
Jul-20-20 Initiated BMO Capital Markets Outperform
Jun-05-20 Initiated Wedbush Outperform
May-11-20 Initiated H.C. Wainwright Buy
Mar-25-20 Initiated ROTH Capital Buy
Jul-11-19 Initiated Chardan Capital Markets Buy
View All

Immunic Inc Stock (IMUX) Latest News

pulisher
Nov 16, 2024

Immunic's IMU-856 shows potential in gastrointestinal health trialsICYMI - Proactive Investors UK

Nov 16, 2024
pulisher
Nov 15, 2024

Immunic, Inc. (NASDAQ:IMUX) Short Interest Update - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Avidity Partners Management LP's Strategic Acquisition in Immuni - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Richard Rudick Spends US$100k On Immunic Stock - Simply Wall St

Nov 15, 2024
pulisher
Nov 15, 2024

Insider Buys Additional US$100k In Immunic Stock - Yahoo Finance

Nov 15, 2024
pulisher
Nov 14, 2024

Janus Henderson Group PLC's Strategic Reduction in Immunic Inc H - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - The Malaysian Reserve

Nov 14, 2024
pulisher
Nov 14, 2024

RTW INVESTMENTS, LP Acquires Additional Shares in Immunic Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Immunic announces publication of IMU-856 data - Yahoo Finance

Nov 14, 2024
pulisher
Nov 13, 2024

Director Richard Rudick Acquires 87,300 Shares of Immunic Inc (I - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

Immunic director Richard Rudick buys $100,368 in stock By Investing.com - Investing.com Australia

Nov 13, 2024
pulisher
Nov 13, 2024

Immunic director Richard Rudick buys $100,368 in stock - Investing.com

Nov 13, 2024
pulisher
Nov 13, 2024

Immunic announces publication of IMU-856 Phase 1 trial data in peer-reviewed journal - Proactive Investors UK

Nov 13, 2024
pulisher
Nov 13, 2024

Immunic reports positive Phase 1 results for celiac disease therapy published in The Lancet - Proactive Investors USA

Nov 13, 2024
pulisher
Nov 13, 2024

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology - PR Newswire

Nov 13, 2024
pulisher
Nov 11, 2024

Immunic, Inc. (NASDAQ:IMUX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 11, 2024
pulisher
Nov 09, 2024

Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges By GuruFocus - Investing.com Canada

Nov 09, 2024
pulisher
Nov 09, 2024

Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic P - GuruFocus.com

Nov 09, 2024
pulisher
Nov 09, 2024

Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges - Yahoo Finance

Nov 09, 2024
pulisher
Nov 08, 2024

Immunic Reports Q3 Earnings and Provides Corporate Update - TipRanks

Nov 08, 2024
pulisher
Nov 08, 2024

Immunic, Inc. Advances MS Trials Amid Financial Update - TipRanks

Nov 08, 2024
pulisher
Nov 08, 2024

Immunic, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 08, 2024
pulisher
Nov 07, 2024

Immunic: Q3 Earnings Snapshot - Milford Mirror

Nov 07, 2024
pulisher
Nov 07, 2024

Immunic Inc (IMUX) Quarterly 10-Q Report - Quartzy

Nov 07, 2024
pulisher
Nov 07, 2024

Immunic Reports Third Quarter 2024 Financial Results and Provides Corporate Update - citybiz

Nov 07, 2024
pulisher
Nov 07, 2024

Immunic highlights progress in multiple sclerosis programs, targets 2025 milestones - Proactive Investors USA

Nov 07, 2024
pulisher
Nov 07, 2024

Immunic CEO details progress following productive third quarter - Proactive Investors UK

Nov 07, 2024
pulisher
Nov 07, 2024

Immunic's Phase 3 MS Trial Advances Despite Wider Q3 Loss; $59.1M Cash Runway | IMUX Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 05, 2024

Immunic's Jessica Breu talks BIO-Europe & MS research advancements - Proactive Investors USA

Nov 05, 2024
pulisher
Nov 05, 2024

Vanguard Group's Strategic Acquisition of Immunic Inc Shares - GuruFocus.com

Nov 05, 2024
pulisher
Nov 04, 2024

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update - Quantisnow

Nov 04, 2024
pulisher
Nov 01, 2024

Immunic (IMUX) Set to Announce Quarterly Earnings on Thursday - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

EQS-News: Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Updateboerse.de - boerse.de

Oct 31, 2024
pulisher
Oct 29, 2024

Immunic to Participate in Industry, Scientific and Investor Conferences in November - StockTitan

Oct 29, 2024
pulisher
Oct 29, 2024

Brokerages Set Immunic, Inc. (NASDAQ:IMUX) PT at $11.20 - MarketBeat

Oct 29, 2024
pulisher
Oct 28, 2024

Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 29.5% in October - MarketBeat

Oct 28, 2024
pulisher
Oct 26, 2024

Reviewing Immunic (NASDAQ:IMUX) & Acasti Pharma (NASDAQ:ACST) - Defense World

Oct 26, 2024
pulisher
Oct 25, 2024

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate - Simply Wall St

Oct 25, 2024
pulisher
Oct 23, 2024

Immunic Therapeutics CMO Dr. Andreas Muehler on Positive Interim Analysis for RMS Trials - Proactive Investors Australia

Oct 23, 2024
pulisher
Oct 23, 2024

Immunic late-stage program for lead asset to proceed as planned - MSN

Oct 23, 2024
pulisher
Oct 22, 2024

Data monitoring committee OKs continuation of phase 3 trial for vidofludimus calcium - Healio

Oct 22, 2024
pulisher
Oct 22, 2024

Interim analysis allows Immunic to stick with phase III MS studies - BioWorld Online

Oct 22, 2024
pulisher
Oct 22, 2024

Immunic stock slips after trial update (IMUX:NASDAQ) - Seeking Alpha

Oct 22, 2024
pulisher
Oct 22, 2024

Immunic Phase 3 MS study advances following positive recommendation from independent committee - Proactive Investors Australia

Oct 22, 2024
pulisher
Oct 22, 2024

Immunic Shares Up 12% on Positive MS Drug Analysis - MarketWatch

Oct 22, 2024
pulisher
Oct 22, 2024

Immunic's phase 3 ENSURE trials for MS drug proceed as planned - Investing.com

Oct 22, 2024
pulisher
Oct 22, 2024

Immunic, Inc. Announces Positive Outcome of Interim Analysis of Phase 3 Ensure Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis - Marketscreener.com

Oct 22, 2024
pulisher
Oct 22, 2024

EQS-News: Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosisboerse.de - boerse.de

Oct 22, 2024
pulisher
Oct 21, 2024

Immunic Stock Set to Rise with Consistent Buy Ratings from Analysts - Nasdaq

Oct 21, 2024

Immunic Inc Stock (IMUX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):